about
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of riskHypertension in Canada: Past, Present, and FutureCanadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): 2014 updateThe 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapyRenal athersosclerotic revascularization evaluation (RAVE study): study protocol of a randomized trial [NCT00127738]The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathyInnovative Approaches to Hypertension Control in Low- and Middle-Income Countries.Heart and Stroke Foundation of Ontario (HSFO) high blood pressure strategy's hypertension management initiative study protocol.DreamTel; Diabetes risk evaluation and management tele-monitoring study protocolA Framework for the Study of Complex mHealth Interventions in Diverse Cultural Settings.The Cardiovascular Health in Ambulatory Care Research Team performance indicators for the primary prevention of cardiovascular disease: a modified Delphi panel study.2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary - an update of the 2010 theme and the science behind new CHEP recommendations.The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.Microalbuminuria in diabetes mellitus.The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk.Effect of nurse-directed hypertension treatment among First Nations people with existing hypertension and diabetes mellitus: the Diabetes Risk Evaluation and Microalbuminuria (DREAM 3) randomized controlled trial.Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial.The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative.I-RREACH: an engagement and assessment tool for improving implementation readiness of researchers, organizations and communities in complex interventions.Statins and renovascular disease in the elderly: a population-based cohort study.Hypertension Analysis of stress Reduction using Mindfulness meditatiON and Yoga (The HARMONY Study): study protocol of a randomised control trial.Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic NephropathyEconomic analysis of Heart and Stroke Foundation of Ontario's Hypertension Management Initiative.Atherosclerotic renovascular disease.Unpacking the Black Box: A Formative Research Approach to the Development of Theory-Driven, Evidence-Based, and Culturally Safe Text Messages in Mobile Health Interventions.More medications, fewer pills: combination medications for the treatment of hypertension.High normal blood pressure and prehypertension: the debate continuesImproving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelinesTreatment of hypertension in patients with nondiabetic chronic kidney disease.Challenges and scientific considerations in hypertension management reflected in the 2012 recommendations of the Canadian Hypertension Education Program.Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetesIMPPACT: Investigation of Medical Professionals and Patients Achieving Control Together.The Canadian Hypertension Education Program - a unique Canadian knowledge translation program.Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10.Hypertension in dialysis and kidney transplant patients.Diabetes risk evaluation and microalbuminuria (DREAM) studies: ten years of participatory research with a First Nation's home and community model for type 2 diabetes care in Northern Saskatchewan.Outcomes of antiproteinuric RAAS blockade: high-dose compared with dual therapy.Measurement of blood pressure in the office: recognizing the problem and proposing the solution.Hypertension in Russia: Changes Observed After 4 Years of a Comprehensive Health System Improvement Program in the Yaroslavl Region.
P50
Q24658014-A065AE95-B0CC-43F6-AA7C-12FD184819F8Q26745487-F5607AB7-A9E6-4497-BD58-4B13144B6DB6Q27348605-B74C5F4C-CC92-4F9B-8F70-95FD19F3CE54Q28211654-94113857-3CFB-4A21-9D69-4005F457C9F8Q28218350-0B5EB43E-368C-42BA-A796-D77F7F701C01Q28237978-E5D8E3D9-175A-4B94-B070-20B7FEE439E8Q30240646-D7C996B7-F1B0-41A3-8A6B-845DAB5753B5Q33391601-203FADFB-4A26-44C2-A001-E17F9E9E32F7Q33442003-6D2A9974-22E6-4B75-85F5-5960FAE1076EQ33639862-FB6159DD-1DDD-4C9B-A0A7-AF7262390FAEQ33874896-01A552CD-83F7-4F0D-9FE2-C78EA33D02FFQ33916665-F001C49A-AA44-4E94-BD7E-BCE7CCED56AAQ33916677-C7BB80D7-029F-4EAA-97D4-15597D8CFD8FQ34004759-011B0572-6817-45C2-8813-5D4A62BA5B72Q34432255-74433AD9-80BC-45DD-98A5-7615C5D25574Q34538367-3AB94D43-46E8-4BFC-BCA4-4B64288A14CEQ34555494-1365F3D2-A62D-45F0-A9A5-7906A8459ABBQ34661652-A3FE8A75-F38E-47F0-8807-BF1969267E93Q35343974-BAE32F4C-F9D4-44E0-828C-5A86832BC6C5Q35585313-CDCC6E52-FE81-4A9A-962A-A23967459B9DQ35670027-CC233012-AF55-4E76-B119-AA585B892147Q35819749-2ACE423E-E9FE-4C03-93F8-3ED87C5E5A9FQ36025568-373FC927-75D3-474F-8310-311C5470C233Q36409170-B5FF0875-96E7-4ACA-8A9F-C4AAE4FB98A7Q36498065-71907277-1FBC-4F94-8E16-1AC656B604F8Q36553037-938ED611-3EA9-4E9A-90E8-FD7EE683EA9CQ36834052-0800773D-CEDA-430C-9205-E73067D21A88Q36834055-50399312-2929-4424-93ED-84BAE1DD8839Q36834059-054F2121-40C5-4CE1-B317-D5FA0B163B32Q36834063-5F39C5EF-CADA-4987-8019-51F752A366D3Q36845564-02980597-E147-45AF-8124-E6672920B6F9Q37076004-3904E339-F567-4A47-A5CE-E3DB55A9C8A8Q37113379-6F34B1B1-319B-4612-8396-5436B750EE32Q37116257-E4A19078-8E61-4B9B-9F55-0572C3E64A4DQ37130485-255158B8-19D8-4DBE-96E6-FA6D58434A6AQ37253882-FB86FA4C-C4C9-488D-88A2-F61971A0BA97Q37259455-3D14F625-C09A-48C4-A417-18E4D84A75C0Q37593679-3C24D34A-784F-4780-A131-9A93CAA01411Q37663723-25E1E310-1EFA-4295-84E1-81F84BCE7C6CQ37664036-ADF3DCB7-DE6F-4801-9D3A-FFD2218F16B3
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0001-7848-3872
@en
name
Sheldon W. Tobe
@ast
Sheldon W. Tobe
@en
Sheldon W. Tobe
@fr
Sheldon W. Tobe
@nl
type
label
Sheldon W. Tobe
@ast
Sheldon W. Tobe
@en
Sheldon W. Tobe
@fr
Sheldon W. Tobe
@nl
altLabel
Sheldon Tobe
@en
Sheldon Tobe
@fr
Sheldon W Tobe
@en
Sheldon W Tobe
@fr
prefLabel
Sheldon W. Tobe
@ast
Sheldon W. Tobe
@en
Sheldon W. Tobe
@fr
Sheldon W. Tobe
@nl
P214
P227
P106
P21
P214
P227
1055860118
P31
P496
0000-0001-7848-3872
P7859
viaf-309722676